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Summary
Suramin is one of the first drugs developed in a
medicinal chemistry program (Bayer, 1916), and it is
still the treatment of choice for the hemolymphatic
stage of African sleeping sickness caused by Trypa-
nosoma brucei rhodesiense. Cellular uptake of sura-
min occurs by endocytosis, and reverse genetic
studies with T. b. brucei have linked downregulation
of the endocytic pathway to suramin resistance.
Here we show that forward selection for suramin
resistance in T. brucei spp. cultures is fast, highly
reproducible and linked to antigenic variation.
Bloodstream-form trypanosomes are covered by a
dense coat of variant surface glycoprotein (VSG),
which protects them from their mammalian hosts’
immune defenses. Each T. brucei genome contains
over 2000 different VSG genes, but only one is
expressed at a time. An expression switch to one
particular VSG, termed VSGSur, correlated with sura-
min resistance. Reintroduction of the originally
expressed VSG gene in resistant T. brucei restored
suramin susceptibility. This is the first report of a link
between antigenic variation and drug resistance in
African trypanosomes.
Introduction
Sleeping sickness, also called human African trypanoso-
miasis (HAT), is still a prevalent disease in sub-Saharan
Africa. It is transmitted by the blood-feeding tsetse flies
and caused by two subspecies of Trypanosoma brucei:
T. b. gambiense causes the chronic form, T. b. rhode-
siense the acute form of HAT. Untreated, both typically
end with coma and death. Among the four currently
available drug therapies, suramin is the oldest one and
is used for the treatment of the first, hemolymphatic
stage of T. b. rhodesiense HAT. Suramin is a big and
highly charged molecule (Supporting Information Fig.
S1) and therefore not able to passively diffuse through
biological membranes. It is supposedly taken up by
receptor-mediated endocytosis (Fairlamb and Bowman,
1980) with an involvement of low-density lipoprotein
(Vansterkenburg et al., 1993). More recent high-
throughput RNAi-screens (Alsford et al., 2012) have
shown a variety of endosomal and lysosomal genes to
render trypanosomes less susceptible to suramin when
knocked-down, which is in agreement with an uptake via
endocytosis. Furthermore, knock-down of the invariant
surface glycoprotein ISG75 led to a 50% reduction of
suramin susceptibility. ISG75 was therefore proposed to
be the binding partner of suramin on the cell surface
(Alsford et al., 2012, 2013). The mode of action of sura-
min has been elusive since it was shown to have
diverse intracellular targets (Wang, 1995).
Despite its use for about a hundred years now, there
have been no reports of suramin resistance in human
pathogenic trypanosomes. The cure-rates of first stage
T. b. rhodesiense HAT are typically high. Suramin treat-
ment failures were mainly observed in context of a miss-
staging of the disease (Pepin and Milord, 1994), since
suramin has a low brain permeability and is ineffective
once the trypanosomes have crossed the blood-brain
barrier. However, suramin resistance is prevalent among
animal pathogenic trypanosomes, for example in T.
evansi isolates from Sudanese camels (El Rayah et al.,
1999) and Chinese buffaloes and mules (Zhou et al.,
2004). Selection for suramin resistance is feasible under
laboratory conditions. After 550 days of in vitro selection
T. evansi were 1800-fold less susceptible to suramin
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(Fang et al., 1994), and T. brucei showed a resistance
factor of 20–140 after in vivo selection with subcurative
doses (Scott et al., 1996). The suramin resistance phe-
notype was lost after transformation of the trypano-
somes to insect-stage, procyclic forms.
We have observed the appearance of strong drug
resistance in T. brucei bloodstream forms after exposure
to high suramin concentrations for only a few days.
Here, we use transcriptomics and reverse genetics
to elucidate the genetic mechanism behind this
phenomenon.
Results
In vitro selection for suramin resistance monitored in
real-time
Isothermal microcalorimetry allows to monitor the growth
of axenic T. brucei cultures in real-time based on the
heat emitted by the cells’ metabolism (Wenzler et al.,
2012). Here, we use the technology to track the emer-
gence of drug resistance. Incubated at presumably
lethal concentrations of suramin, i.e., the 5-fold and 25-
fold of the IC50, T. b. rhodesiense bloodstream-form cul-
tures appeared to be dead after two days, started to
regrow after three, and had fully recovered by day five
(Fig. 1). This phenomenon was consistently observed:
we have performed the same experiment with T. b. bru-
cei, which also recovered from suramin pressure within
one week. In all cases, the recovered trypanosomes
were suramin-resistant by factors between 30 and 100
as compared to the starting population. No such phe-
nomenon was observed with other drugs: melarsoprol or
pentamidine completely killed the T. brucei cultures at
concentrations of 5- and 25-fold their IC50 (Wenzler
et al., 2012) (Fig. 1).
Rapid emergence of resistance also in clonal
populations
The microcalorimetric experiment was performed with
an inoculum of 105 cells. To rule out that a subpopula-
tion of suramin-resistant trypanosomes had been pres-
ent all along and was simply selected for under drug
pressure, we repeated the experiment with fresh T. b.
rhodesiense STIB900 clones. Incubated at concentra-
tions between 500 and 1700 nM suramin (i.e., 5–80 fold
their respective IC50), drug-resistant progeny was again
obtained within one week for all tested clones [n5 11].
Table 1 summarizes the results for one clone (named
T. b. rhodesiense STIB900_c1) and four independent
suramin-resistant derivatives thereof (named T. b. rhode-
siense STIB900_c1_sur1 to _sur4), selected at 1050 nM
suramin (80-fold the IC50). All four derivatives were at
least 90-fold resistant to suramin as compared to the
parent clone STIB900_c1 (p< 0.0001 by One Way
ANOVA with Tukey’s multiple comparisons test). While
their sensitivity to melarsoprol and pentamidine was
unchanged (Table 1), the suramin-resistant lines were
cross-resistant to the structurally related trypanocidal
dye trypan blue (p<0.001, Ehrlich, 1904; Supporting
Information Fig. S1). The cross-resistance phenotype
was stable in the absence of drug pressure for several
weeks. After 80 days of cultivation, however, the resist-
ance factor had decreased to 10- to 50-fold in the four
lines (Fig. 2). Cumulative growth curves (Supporting
Information Fig. S2) demonstrate slightly longer popula-
tion doubling times of the resistant derivatives (8.2 h for
Fig. 1. Bloodstream-form T. brucei incubated with presumably lethal concentrations of suramin rapidly became resistant and regrew. No such
phenomenon was observed with the drugs melarsoprol or pentamidine.
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STIB900_c1_sur1 and 8.3 h for STIB900_c1_sur4) as
compared to the suramin sensitive parent clone (7.7 h).
VSGs are differentially expressed in resistant and
sensitive parasites
The finding that suramin resistance reproducibly devel-
oped even in cultures from freshly cloned trypanosomes,
indicated that the underlying mutation – whatever its
nature – had occurred during the selection period. How-
ever, the reproducible acquisition of a particular point
mutation is unlikely to happen within days. We, there-
fore, reckoned the mechanism of suramin resistance
more likely to be reflected at the level of gene expres-
sion than gene sequence. Total RNA from T. b. rhode-
siense STIB900_c1 and the four selected lines, grown in
the absence of suramin, was subjected to quantitative
transcriptomics by mRNA-Seq. Over 50 million high-
quality reads were obtained for each line (European
Nucleotide Archive accession PRJEB20650). As
expected given the short interval between suramin-
sensitive parent and suramin-resistant derivatives, there
were hardly any differences in transcript abundance
(Supporting Information Fig. S3). Genes encoding pro-
teins that had been shown to be involved in suramin
resistance in T. brucei (Alsford et al., 2012), i.e., the
invariant surface glycoprotein ISG75, the putative major
facilitator superfamily transporter MFST or the lysosomal
proteins CatL, CBP1 and GLP-1, were not differentially
expressed in the suramin-resistant lines. The only hits
that were differentially expressed mapped to VSG genes
(Supporting Information Fig. S3). Thus all four selected
lines had undergone an expression switch to a new
VSG.
The suramin-resistant lines have all switched to the
same VSG
The sequence of this newly expressed VSG was recon-
structed by de novo assembly from the Illumina reads.
The reconstructed sequence was verified by reverse
transcriptase PCR followed by direct sequencing, mak-
ing use of the fact that all T. brucei mRNAs possess the
same spliced leader sequence at the 50 end (Parsons
et al., 1984). Three of the four resistant lines had
switched to the identical VSG gene, which was termed
VSGSur (GenBank accession MF093647). T. b. rhode-
siense STIB900_c1_Sur2 expressed a gene that was
almost identical to VSGSur (GenBank accession
MF093648), differing only in four SNPs (two of which
were non-synonymous) and a different 30 UTR. The
sequence of the VSG expressed in the parental clone
STIB900_c1 was reconstructed in the same way and
termed VSG900 (GenBank accession MF093646). Re-
mapping of the Illumina reads upon inclusion of these
two VSG sequences resulted in more than 10% of reads
mapping to VSG900 in the sensitive parent clone, and
more than 10% of reads mapping to VSGSur in all the
resistant derivatives (Fig. 3). Reverse-transcriptase
qPCR confirmed the switch from VSG900 to VSGSur in
the resistant lines as they all showed a more than
10,000-fold upregulation of VSGSur (Fig. 4). We also
analyzed the suramin-selected derivatives of another
Table 1. Drug sensitivities of the parental clone T. b. rhodesiense STIB900_c1 and four independently selected derivatives (sur1–4). Values
are 50% inhibitory concentrations in nM6 standard deviation (n 5)
Suramin Trypan Blue Melarsoprol Pentamidine
STIB900_c1 1364 27006900 226 1.2 1.16 0.4
STIB900_c1_sur1 1250640 16,20065600 236 2.3 1.06 0.3
STIB900_c1_sur2 1240610 16,30065300 246 1.9 1.56 1.1
STIB900_c1_sur3 1240690 16,30065200 246 2.2 1.26 0.5
STIB900_c1_sur4 12706100 16,60065700 266 3.3 1.56 1.2
Fig. 2. Stability of suramin resistance in the absence of selection.
The resistance factor was defined as the IC50 of the derivatives
of T. b. rhodesiense STIB900_c1 divided by the IC50 of
T. b. rhodesiense STIB900_c1 itself, grown in parallel.
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clone of T. b. rhodesiense STIB900 (STIB900_c2), and
they had switched to VSGSur as well (Fig. 4). Moreover,
the suramin-resistant population derived from T. b. bru-
cei strain BS221 had undergone a switch to a VSG with
97% nucleotide sequence identity (Needleman-Wunsch
global alignment) to VSGSur (Fig. 4; GenBank accession
MF093649).
Suramin resistance correlates with expression of
VSGSur but not ESAG7
VSGSur encodes a bona fide variant surface glycoprotein
of 491 amino acids with an N-terminal export signal and
a C-terminal GPI-anchoring signal as predicted by Sig-
nalP (Nielsen et al., 1997) and GPI-SOM (Fankhauser
and M€aser, 2005), respectively. Profile scans against
the Procite and Pfam databases of sequence motifs did
not return significant hits beside the entry for the T. bru-
cei VSG conserved C-terminal domain (PF10659;
E-value of 0.0002). A Blastp search with VSGSur as the
query against the non-redundant protein sequence data-
base at NCBI returned significant hits on variant surface
glycoproteins, the best one on VSG 522 (GenBank:
AGH61081.1) with a sequence identity of 72%. The
same search against all organisms other than
Trypanosoma spp. did not return a single hit. In the
absence of any particular feature that would distinguish
it from other VSGs, we initially presumed that it is not
VSGSur itself that caused drug resistance but one of the
expression site associated genes (ESAGs), which are
polycistronically co-transcribed with each VSG and
which could have failed to correctly map due to
sequence divergence between STIB900 and the refer-
ence sequence used. If an antigenic switch results from
activation of a new VSG expression site, new alleles of
ESAGs will be expressed as well. If the switch is due to
replacement of the active VSG by gene conversion, the
expressed ESAGs will remain the same.
ESAG7 encodes the non-anchored part of the hetero-
dimeric transferrin receptor and differs in sequence
among the T. brucei VSG expression sites (van Luenen
et al., 2005; Hertz-Fowler et al., 2008). For each of the
five sequenced T. b. rhodesiense lines, the whole tran-
scriptome was assembled de novo from the Illumina
reads and the expressed ESAG7 was extracted using a
blast search (Tb927.7.3260, 2175 nt). Three of the
suramin-resistant lines expressed exactly the same
ESAG7 gene as the parental T. b. rhodesiense
STIB900_c1 (GenBank accession MF093650); the
fourth expressed an ESAG7 that differed in five nucleo-
tides, two of which were non-synonymous (GenBank
accession MF093651). Thus in one of the suramin-
selected lines, the switch to VSGSur appears to have
occurred by activation of a new expression site, while in
the remaining three it happened by gene conversion,
replacing the originally expressed VSG900 gene while
maintaining the ESAGs. This strongly suggests that it is
the expression of VSGSur itself, and not of the ESAGs,
that causes suramin resistance. This hypothesis was
corroborated by reverse genetic manipulation of VSG
expression.
Fig. 3. Differential gene expression of resistant derivatives vs.
suramin-sensitive parental T. b. rhodesiense STIB900 clone as
analyzed with DESeq2. Illumina reads were mapped to the
TREU927 reference genome supplemented with Lister 427
bloodstream expression sites and with the sequences of VSGSur
and VSG900. The x-axis displays transcript abundance (mean read
count over all samples normalized for library size) and the y-axis
displays the logarithmic fold-change of transcript abundance (all
four resistant derivatives vs. the sensitive parent clone). Genes with
a significant (p< 0.01) fold-change are colored in red if
overexpressed, and in blue if underexpressed in the resistant
derivatives.
Fig. 4. Expression of VSGSur and VSG900 as determined by qRT-
PCR in resistant T. b. rhodesiense and T. b. brucei, normalized to
telomerase reverse transcriptase (TERT).
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Reversal of the VSG900-VSGSur switch restores suramin
sensitivity
We made a genetic construct (Fig. 5A) to target the
active VSG expression site of the suramin-resistant T. b.
rhodesiense STIB900_c1_sur1. In order to exchange
the expressed VSGSur with VSG900, the construct was
framed with the 5’ and 3’ UTR of VSGSur and contained
the coding sequence of VSG900 together with a
blasticidin resistance gene. Positive transfectants were
selected with blasticidin and cloned by limiting dilution.
The construct had integrated in the genomes of all the
analyzed clones [n5 6] as determined by PCR using
primers binding to the 50 and 30 UTR of VSGSur as the
adjacent genomic context was unknown. Reverse-
transcriptase qPCR confirmed a high expression of the
re-introduced VSG900 (Fig. 5B). Subsequent drug sensi-
tivity assays with three of the transfectants showed a
complete loss of resistance in all of them, with IC50 val-
ues between 10 and 12 nM (Fig. 5C). One of the trans-
fectants was once more subjected to suramin pressure.
It quickly reestablished suramin resistance with a resist-
ance level similar to STIB900_c1_sur1 (Fig. 6). Since
these re-selected parasites could have undergone either
expression site switch or gene conversion in order to re-
express VSGSur, we investigated three lines selected
from one transfectant by PCR using primers binding to
the 50 and 30 UTR of VSGSur. Two of them
(c1_sur1_900a_sur1 and c1_sur1_900a_sur2) had lost
the construct, thus had undergone a gene conversion in
order to switch back to VSGSur. In the third line
(c1_sur1_900a_sur3) the construct was still present,
therefore it had undergone an expression site switch in
order to express VSGSur. We subsequently exposed the
three lines to blasticidin; as expected the two lines that
had undergone gene conversion were killed. The line
that had undergone an expression site switch recovered
under blasticidine pressure and the obtained parasites
(c1_sur1_900a_sur3_bl1, _bl2 and _bl3) had completely
lost the suramin resistance (Fig. 6).
Fig. 5. Reverse genetic re-introduction of VSG900. A) Schematic
illustration of VSGSur (top) and the construct (bottom) used for re-
introduction of VSG900 into the active bloodstream expression site
of the resistant derivative STIB900_c1_sur1. The construct is
framed with the 50 and 3’ untranslated region (UTR) of VSGSur, it
contains a blasticidin resistance gene (BSD), an ab tubulin splice
site (ab tub) and the coding sequence (cds) of VSG900. Binding
sites of primers used for the verification of the genomic integration
of the construct are indicated with black arrows. B) qRT-PCR,
normalized with TERT. Expression of VSGSur (red) and VSG900
(blue) are shown for STIB900_c1_sur1 and six transfected clones
thereof, with VSG900 introduced into the active bloodstream
expression site. C) Suramin dose-response curves for
STIB900_c1_sur1 and three transfected clones expressing VSG900.
Fig. 6. Ups and downs of suramin sensitivity in the course of the
experiment. IC50 values are shown for the sensitive parent clone c1
before selection (dark blue), one of the resistant derivatives after
suramin selection (dark red), a transfected clone thereof with
VSG900 re-introduced into the active bloodstream expression site
(blue), one suramin selected derivative of that clone (light red), and
three blasticidine selected lines thereof (light blue).
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Binding and uptake of trypan blue
We exploited the facts that the suramin-selected lines
were cross-resistant to trypan blue, and that trypan blue
becomes fluorescent when bound to protein (Avelar-
Freitas et al., 2014), to further examine the observed
phenomenon of drug resistance. The fluorescence of
trypanosomes was quantified by flow cytometry after
incubation for two hours with different concentrations of
trypan blue (Fig. 7). Since dead cells are strongly
perfused by trypan blue, we first compared dead and liv-
ing cells. The dead cells showed a much higher fluores-
cence and could be clearly separated from the living
cells by setting the gate accordingly in a cell-size versus
fluorescence plot (Supporting Information Fig. S4).
Fluorescence of living cells incubated at physiological
temperature is derived from both, surface bound and
endocytosed trypan blue. At 378C the two tested resist-
ant derivatives (STIB900_c1_sur1 and STIB900_c1_
sur4) showed significantly lower fluorescence levels
when compared to the sensitive parent clone (STIB900_
c1) over all concentrations (Fig. 7A). As endocytosis in
trypanosomes is inactivated at low temperatures
(Brickman et al., 1995), we performed the same experi-
ment at 48C to quantify the fluorescence of
surface-bound trypan blue (Fig. 4B). The resistant
parasites showed similar levels of fluorescence as the
sensitive clone at concentrations of 5–200 mg ml21 but
significantly differed at 390 mg ml21, where the sensitive
clone showed a strong increase in fluorescence. If the
fluorescence at 378C represents binding plus uptake,
and the fluorescence at 48C represents binding, then
the curve obtained by subtraction (Fig. 7C) represents
the trypan blue which had been endocytosed during the
two hours of incubation. These values were lower for
the resistant parasites than for the sensitive clone at
concentrations up to 200 mg ml21. There was no differ-
ence at 390 mg ml21 trypan blue, possibly due to toxicity
and inhibition of endocytosis in the sensitive clone.
Discussion
The famous parasitologist Frank Hawking (father of the
even more famous physicist Stephen Hawking) stated
that ‘Strains of trypanosomes may be made suramin-
resistant in the laboratory, but this resistance takes
much longer to develop than with arsenicals’ (Hawking,
1963). Here we show that>90-fold suramin resistance
emerges in T. brucei spp. bloodstream forms after only
few days of in vitro selection at high drug pressure. In
contrast, it had taken us almost two years to select for
melarsoprol-resistant derivatives of T. b. rhodesiense
STIB900 with resistance factors of the same magnitude
(Bernhard et al., 2007). Comparative analysis of gene
expression showed an association of a particular VSG
with suramin resistance. Our first suspicion, that VSGSur
was only a marker and the actual cause of resistance
was one of the ESAGs, was rebuted by the finding that
three of the four resistant lines had switched their VSG
gene while maintaining the VSG expression site, as indi-
cated by perfect conservation of expressed ESAG7. The
finding that one of the resistant lines expressed a
slightly different ESAG7 indicated that VSGSur in
Fig. 7. Fluorescence of suramin sensitive and resistant cells
incubated at different concentrations of trypan blue for two hours.
Significantly different fluorescence levels between the sensitive and
the resistant lines are indicated (*, p< 0.05; **, p< 0.01; **,
p< 0.001; n 5, pairwise t-test); there were no significant
differences between the two resistant lines. (A) Cells incubated at
378C: the fluorescence levels represent surface bound plus
endocytosed trypan blue. (B) Cells incubated at 48C: the
fluorescence levels represent surface-bound trypan blue. (C) The
difference between the fluorescence at 378C and 48C therefore
represents an estimate of the endocytosed trypan blue.
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parental T. b. rhodesiense STIB900 localized to a
(silent) telomeric VSG expression site rather than to the
chromosome-internal or minichromosomal VSG reposi-
tory (El-Sayed et al., 2000). The suramin resistance
phenotype was slowly reversible over time, which might
be explained by the slightly longer population doubling
times of the resistant derivatives.
The causality between VSGSur expression and sura-
min resistance was confirmed by reverse genetic re-
introduction of the originally expressed VSG into the
resistant parasites, which completely restored suscepti-
bility. The finding that the expression of VSGSur causes
suramin resistance, explains the fast emergence of the
resistance and the high reproducibility of the in vitro
selection. It also explains the discrepancy with Hawk-
ing’s observation cited above, because he was using
subcurative treatment of infected mice to select for
resistance (in vitro cultivation of T. brucei was not possi-
ble at the time).
In vivo, parasites that are bound to express a particular
VSG under suramin pressure will be eliminated by host
antibodies. This might be the reason why suramin, after
one century of use, is still effective in the treatment of
early-stage east-African sleeping sickness. The commonly
used regimen is five injections of 20 mg kg21, leading to
suramin plasma levels over 100 mg ml21 for several
weeks (Burri et al., 2004), which is clearly above the in
vitro IC50 of trypanosomes expressing VSG
Sur. The situa-
tion would be different if lower doses of suramin were
administered. One could speculate that such a mecha-
nism could have facilitated the emergence of suramin
resistance in animal-pathogenic trypanosomes, as the
usual treatment regimen in horses and camels is a single
dose of 10 mg kg21 suramin, and the disease typically
leads to immunosuppression (Giordani et al., 2016). Thus
if the trypanosomes escaped the effects of suramin in the
short term by switching to a certain VSG, this would give
them more time to develop other resistance mechanisms.
It has been reported that a functional immune system is
important for effective suramin treatment of animal trypa-
nosomiasis (Leach and Roberts, 1981).
VSGs could be either directly or indirectly involved in
binding and uptake of suramin, and VSGSur might be
non-functional in this respect. Previous studies which
proposed an uptake of suramin via endocytosis
(Fairlamb and Bowman, 1980; Vansterkenburg et al.,
1993) are in accordance with this, as VSG in T. brucei
bloodstream forms is endocytosed at a very high rate
(Engstler et al., 2004). An involvement of VSG in sura-
min binding or uptake could also explain the insensitivity
of procyclic trypanosomes to suramin (Scott et al.,
1996) as they do not express VSG genes.
Binding of trypan blue at 48C to suramin-sensitive try-
panosomes suggests a saturable high-affinity component
plus a low affinity component that becomes apparent at
390 mg ml21 trypan blue (testing of higher concentrations
was not possible because of toxicity and solubility prob-
lems). This implies the presence of more than one bind-
ing partner on the cell surface of the sensitive clone. The
low affinity component appeared to be missing in the
suramin-resistant clones (Fig. 7B). However, the uptake
of trypan blue at 378C by the suramin-resistant lines was
impaired at concentrations between 5 and 200 mg ml21
(Fig. 7C), indicating that the low-affinity binding compo-
nent may not be responsible for drug resistance. Thus
while the genetic basis for fast suramin resistance in T.
brucei is an expression switch to VSGSur, the biochemical
basis remains to be elucidated.
Experimental procedures
T. brucei isolates and cultivation
The T. b. rhodesiense strain STIB900 is a derivative of
STIB704, which was originally isolated from a male patient
at St. Francis Hospital in Ifakara, Tanzania in 1982. It was
passaged several times in rodents and once in a tsetse fly
(Glossina morsitans morsitans) before a cloned population
was adapted to axenic in vitro culture. T. brucei BS221 was
received from Dr. Sam Black, International Laboratory for
Research on Animal Diseases (ILRAD, Kenya). Parasites
were cultivated in Iscove’s Modified Dulbecco’s Medium
supplemented according to Hirumi (Hirumi and Hirumi,
1989) with 15% of heat-inactivated horse-serum. The para-
sites were grown at 378C, 5% CO2 and diluted three times
a week.
Microcalorimetry with T. b. rhodesiense
T. b. rhodesiense strain STIB900 were cultivated in Mini-
mum Essential Medium with Earle’s salts, supplemented
according to Baltz et al. (Baltz et al., 1985) with minor mod-
ifications: 0.2 mM 2-mercaptoethanol, 1 mM sodium pyru-
vate, 0.5 mM hypoxanthine and 15% heat-inactivated horse
serum. Trypanosome cultures in the late exponential growth
phase were diluted with fresh culture medium to a density
of 105 cells ml21. Ampoules were filled, in triplicate, with
3 ml cell suspension and supplemented with suramin, pent-
amidine or melarsoprol at concentrations corresponding to
5 3 IC50 or 25 3 IC50 in the identical medium (Wenzler
et al., 2012). Culture medium without trypanosomes served
as baseline control. The heat flow was measured continu-
ously over a period of 8 days at 378C in a TAM III isother-
mal microcalorimeter (thermal activity monitor, model 249;
TA instruments, New Castle DE, USA).
Cloning of T. b. rhodesiense
A microdrop of a suspension with 104 cells ml21 was made
using a gilded paperclip and inspected by two persons
under an inverted microscope. After confirmation of the
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presence of a single cell, the microdrop was supplemented
with 50 ml of cloning medium. This consisted of 59%
Iscove’s modified Dulbecco’s Medium, which had been sup-
plemented according to Hirumi (Hirumi and Hirumi, 1989)
for a total volume of 100%, 1% M€aser-mix (M€aser et al.,
2002), 20% inactivated horse-serum and 20% of pre-
conditioned medium. The pre-conditioned medium was pre-
pared by centrifugation of a dense trypanosome culture (10
min at 1840 g) and subsequent sterile filtering of the super-
natant. After four days of incubation at 378C, 5% CO2, the
plate was inspected under an inverted microscope and 50
ml of cloning medium was added to the wells with a growing
clonal colony. After another 3 days the clones were pas-
saged to new plates and cultivated as described above.
In vitro selection for drug resistance and determination
of growth rates
A fresh clone of T. b. rhodesiense STIB900 in the exponen-
tial growth phase was selected with 1050 nM suramin in
four wells each containing 1 ml medium with 5 3 104 cells.
After 6 days the parasites were removed from drug pres-
sure by washing three times with fresh culture medium and
cultured in drug-free medium as described above. For the
BS221 strain 105 cells were selected with 1070 nM
(BS221_sur1) and 4270 nM (BS221_sur2) suramin and
removed from drug pressure after 5 days. Cell growth was
measured between day 15 and day 26 after selection.
Cumulative growth curves were determined by dilution of
the cells to 105 ml21, incubation for 24 h, and measurement
of cell density with a CASY Cell Counter (OMNI Life Sci-
ence, Bremen). This procedure was repeated for four days.
Cumulative cell numbers and the population doubling times
were calculated and statistically evaluated with t-tests
applying Benjamini-Hochberg correction using R Studio (R
version 3.3.3).
Alamar blue assay
Suramin sodium salt and pentamidine isethionate were
obtained from Sigma (S2671 and P0547 respectively), Try-
pan Blue from Fluka (93590) and melarsoprol from Sanofi-
Aventis/WHO. Alamar blue assays (R€az et al., 1997) for
determination of in vitro drug sensitivities were carried out
at least three times independently. Serial drug dilutions
were prepared on a 96 well plate in technical duplicates
and cells were added in a concentration of 2 3 104.
Parasite-free, drug-free wells were used for determination
of background fluorescence. After an incubation time of
69 h, plates were inspected microscopically and resazurin
was added to a final concentration of 36 mM. Fluorescence
intensity was measured after 3–4 h incubation using a
SpectraMax (Molecular Devices) and SoftMax Pro 5.4.5
software. The 50% inhibitory concentrations (IC50) were
calculated with GraphPad Prism 6.00 using a non-linear
regression model to fit the dose-response curve (variable
slope; four parameters, bottom value set to zero). Statistical
analysis was performed with GraphPad Prism 6.00 using
an ordinary one-way ANOVA with Tukey’s multiple compari-
sons test.
Extraction of RNA, mRNA-seq and comparative
transcriptomics
Cultures in the exponential growth phase were centrifuged
and washed once with PBS before total RNA was isolated
using the RNeasy Mini Kit (Qiagen) including an on-column
DNase treatment. RNA was shock-frozen in liquid nitrogen
and stored at 2808C. Five microgram of RNA from two
independent isolations were pooled for each sample.
Library preparation and sequencing was performed at the
Quantitative Genomics Facility (QGF) of the ETH Zurich in
Basel. Sequencing libraries were prepared using the Tru-
Seq Stranded mRNA Library preparation kit (Illumina).
Single-end sequencing of 125 nucleotides was carried out
on an illumina HiSeq 2500. The bioinformatic analysis was
carried out on the sciCORE cluster of the University of
Basel. Quality of the sequencing reads was controlled with
fastqc software (Babraham Bioinformatics - FastQC A Qual-
ity Control tool for High Throughput Sequence Data. Avail-
able at: http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/. Accessed: 6th April 2017). Illumina adaptors, low
quality ends and reads with a length of fewer than 36 nucle-
otides were removed with trimmomatic (Bolger et al., 2014).
Sequencing reads were mapped to the TREU927 reference
genome (version TriTrypDB-28) complemented with blood-
stream expression sites from Lister427 (Hertz-Fowler et al.,
2008). Mapping was performed with bwa (Li and Durbin,
2009) using the default parameters (seedlength of 19 nucle-
otides, matching score of 1, mismatch penalty of 4, gap
open penalty of 6 and a gap extension penalty of 1). The
alignment files in the SAM format were converted to binary
files using samtools (Li et al., 2009) and sorted and indexed
using picard tools (Broad Institute. Available at: http://broad-
institute.github.io/picard/. Accessed: 6th April 2017). Read
counts per transcript were determined with the Python
package HTSeq (Anders et al., 2015) using a combined gff
file from TREU927 (version TriTrypDB-28) and bloodstream
expression sites from Lister427 (Hertz-Fowler et al., 2008),
default parameters with a minimal mapping quality of 10
were used. Raw counts were analyzed with the R package
DESeq2 (Love et al., 2014) (version 1.14.1), independent
filtering was disabled.
The de novo assembly of transcripts was carried out
using trinity (Grabherr et al., 2011) with the default parame-
ters. The de-novo assembled transcripts were screened
with blastn for ESAG7-like genes using the sequence of
gene Tb927.7.3260 as query.
Reverse transcription, PCR and quantitative PCR
Complementary DNA (cDNA) was synthesized with Super-
Script III Reverse Transcriptase (Invitrogen via Thermo
Fisher Scientific, Waltham MA, USA) according to the man-
ufacturer’s protocol using oligo(dT) primer and 1–5 mg of
total RNA. One microliter of the 1:100 diluted cDNA was
used for PCR. Amplification of the VSGs was performed
with one primer binding to the spliced leader sequence
(Parsons et al., 1984) at the 50 UTR and the other primer
binding to the 30 end of the gene (Supporting Information
Table S1). The sequences of the 30ends were derived from
the de-novo assembly. For amplification of the VSG
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expressed in the BS221 strain, a primer binding unspecifi-
cally to the 30ends of all VSGs (Aline et al., 1985) was used
(Supporting Information Table S1). The PCR was carried
out with Taq polymerase (Solis BioDyne, Estonia) or with
KAPA HiFi HotStart DNA Polymerase (Kapa Biosystems,
Cape Town, South Africa). PCR products were run on a 1%
agarose gel, which was subsequently stained with GelRed
Nucleic Acid Gel Stain (Biotium, Fremont CA, USA). The
PCR products were purified with the Wizard SV Gel and
PCR Clean-Up System (Promega, Madison WI, USA) or
the NucleoSpin Gel and PCR Clean-up (Macherey-Nagel,
D€uren, Germany) and sent to Microsynth (Balgach,
Switzerland) for sequencing. Primers for sequencing
were the same as used for PCR, additional internal primers
were designed for completion of the sequences. Quantita-
tive PCR was carried out with Power SYBR Green (Applied
Biosystems via Thermo Fisher Scientific) on a StepOnePlus
real-time PCR System (Applied Biosystems) in technical
duplicates. StepOne Software v2.3 was used for analysis of
the amplification plots and calculation of the CT values,
which were normalized to the housekeeping gene telomer-
ase reverse transcriptase (Brennd€orfer and Boshart, 2010)
(TERT; D CT). All primers (Supporting Information Table
S1) were designed using the Primer3Plus software (Avail-
able at: http://primer3plus.com/cgi-bin/dev/primer3plus.cgi.
Accessed: 6th April 2017)
Reverse genetics with T. brucei
For the gene exchange of VSGSur to VSG900 a construct
was designed (Fig. 5A) containing the 30 and 50 UTRs of
VSGSur, the coding sequence of VSG900, an ab tubulin
splice site and a blasticidin-resistance gene (BSD). The
DNA was synthesized by GenScript (Piscataway Township
NJ, USA) and integrated between the HindIII and the
EcoRI-site of a pUC57 vector. For amplification of the insert
a PCR was performed using two flanking primers. Three
microgram of the purified PCR product were used for the
transfection of 4 3 107 STIB900_c1_sur1 cells in 100 ml
Tb-BSF buffer (Schumann Burkard et al., 2011) with an
Amaxa Nucleofector using program Z-001. Positive trans-
fected clones were obtained by limiting dilution in standard
culture medium. After 24 h of incubation, blasticidin was
added to a total concentration of 5 mg ml21. The construct
integration was verified by PCR on genomic DNA: As the
flanking genomic sequences upstream and downstream of
VSGSur are unknown, primers binding to the 50 and 30 UTR
of VSGSur were used for the PCR (Fig. 5), which resulted
in a band of 1624 nucleotides derived from the wildtype
sequence of VSGSur and a second band of 2356 nucleo-
tides in the presence of the construct. Genomic DNA was
isolated from 10 ml dense culture in the following manner:
The culture was centrifuged at 1800 g for 5 min and
washed with TE buffer (10 mM TrisHCl pH 8, 1 mM EDTA)
once. Cells were eluted in 100 ml TE buffer and lysed by
addition of 1 ml of 10% SDS and incubation for 10 min at
558C. Subsequently 30 ml of 5 M potassium acetate were
added to the lysate and incubated on ice for 5 min to pre-
cipitate SDS and proteins. The lysate was spun down for 5
min at full speed in a microcentrifuge and the supernatant
transferred to a new tube. The DNA was precipitated with
absolute ethanol, washed with 70% ethanol and eluted in
20 ml H2O. PCR was carried out as described above. The
expression of VSGSur and VSG900 was measured by quan-
titative PCR as described above.
Trypan blue binding and uptake
A total of 2 3 105 parasites per sample was exposed to try-
pan blue (5, 20, 50, 200 or 390 mg ml21) in 1 ml standard
growth medium and incubated for two hours at 378C or
48C. After incubation, the parasites were centrifuged (5 min,
3000 g) and washed twice with 1 ml PBS (Phosphate-buf-
fered saline; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.4) at room temperature or 48C
respectively. The cells were resuspended in 250 ml PBS fol-
lowed by the addition of 250 ml 10% formalin for fixation.
The fluorescence intensity of the fixed cells was measured
with a BD FACSCaliburTM flow cytometer (BD Biosciences,
San Jose, CA, USA) using the FL3 channel (670 nm long
pass) upon excitation at 488 nm. Ten thousand events were
acquired within the parasite gate based on size versus
granularity (FSC x SSC). Dot plots and their fluorescence
were evaluated in FL3 histograms as trypan blue has its
emission peak at 660 nm (Avelar-Freitas et al., 2014). The
measured fluorescence intensity was analyzed with Flowing
Software (Version 2.5.1) by using a living parasite gate
based on size versus fluorescence intensity (FSC x FL3)
and statistically evaluated with R Studio, applying pairwise
t-tests (Version 1.0.143, R version 3.3.3).
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